TY - JOUR
T1 - Costs and resource utilization for diagnosis and treatment during the initial year in a european inflammatory bowel disease inception cohort
T2 - An ECCO-EpiCom study
AU - Burisch, Johan
AU - Vardi, Hillel
AU - Pedersen, Natalia
AU - Brinar, Marko
AU - Cukovic-Cavka, Silvja
AU - Kaimakliotis, Ioannis
AU - Duricova, Dana
AU - Bortlik, Martin
AU - Shonová, Olga
AU - Vind, Ida
AU - Avnstrøm, Søren
AU - Thorsgaard, Niels
AU - Krabbe, Susanne
AU - Andersen, Vibeke
AU - Dahlerup, Jens F.
AU - Kjeldsen, Jens
AU - Salupere, Riina
AU - Olsen, Jóngero
AU - Nielsen, Kári R.
AU - Manninen, Pia
AU - Collin, Pekka
AU - Katsanos, Konstantinnos H.
AU - Tsianos, Epameinondas V.
AU - Ladefoged, Karin
AU - Lakatos, Laszlo
AU - Bailey, Yvonne
AU - O'Morain, Colm
AU - Schwartz, Doron
AU - Lupinacci, Guido
AU - De Padova, Angelo
AU - Jonaitis, Laimas
AU - Kupcinskas, Limas
AU - Turcan, Svetlana
AU - Barros, Louisa
AU - Magro, Fernando
AU - Lazar, Daniela
AU - Goldis, Adrian
AU - Nikulina, Inna
AU - Belousova, Elena
AU - Fernandez, Alberto
AU - Pineda, Juan R.
AU - Almer, Sven
AU - Halfvarson, Jonas
AU - Tsai, Her Hsin
AU - Sebastian, Shaji
AU - Friger, Michael
AU - Greenberg, Dan
AU - Lakatos, Peter L.
AU - Langholz, Ebbe
AU - Odes, Selwyn
AU - Munkholm, Pia
N1 - Publisher Copyright:
© 2014 Crohn's & Colitis Foundation of America, Inc.
PY - 2015/1/1
Y1 - 2015/1/1
N2 - Background: No direct comparison of health care cost in patients with inflammatory bowel disease across the European continent exists. The aim of this study was to assess the costs of investigations and treatment for diagnostics and during the first year after diagnosis in Europe. Methods: The EpiCom cohort is a prospective population-based inception cohort of unselected inflammatory bowel disease patients from 31 Western and Eastern European centers. Patients were followed every third month from diagnosis, and clinical data regarding treatment and investigations were collected. Costs were calculated in euros (€) using the Danish Health Costs Register. Results: One thousand three hundred sixty-seven patients were followed, 710 with ulcerative colitis, 509 with Crohn's disease, and 148 with inflammatory bowel disease unclassified. Total expenditure for the cohort was €5,408,174 (investigations: €2,042,990 [38%], surgery: €1,427,648 [26%], biologicals: €781,089 [14%], and standard treatment: €1,156,520 [22%)]). Mean crude expenditure per patient in Western Europe (Eastern Europe) with Crohn's disease: investigations €1803 (€2160) (P = 0.44), surgery €11,489 (€13,973) (P = 0.14), standard treatment €1027 (€824) (P = 0.51), and biologicals €7376 (€8307) (P = 0.31). Mean crude expenditure per patient in Western Europe (Eastern Europe) with ulcerative colitis: investigations €1189 (€1518) (P < 0.01), surgery €18,414 (€12,395) (P = 0.18), standard treatment €896 (€798) (P < 0.05), and biologicals €5681 (€72) (P = 0.51). Conclusions: In this population-based unselected cohort, costs during the first year of disease were mainly incurred by investigative procedures and surgeries. However, biologicals accounted for >15% of costs. Long-term follow-up of the cohort is needed to assess the cost-effectiveness of biological agents.
AB - Background: No direct comparison of health care cost in patients with inflammatory bowel disease across the European continent exists. The aim of this study was to assess the costs of investigations and treatment for diagnostics and during the first year after diagnosis in Europe. Methods: The EpiCom cohort is a prospective population-based inception cohort of unselected inflammatory bowel disease patients from 31 Western and Eastern European centers. Patients were followed every third month from diagnosis, and clinical data regarding treatment and investigations were collected. Costs were calculated in euros (€) using the Danish Health Costs Register. Results: One thousand three hundred sixty-seven patients were followed, 710 with ulcerative colitis, 509 with Crohn's disease, and 148 with inflammatory bowel disease unclassified. Total expenditure for the cohort was €5,408,174 (investigations: €2,042,990 [38%], surgery: €1,427,648 [26%], biologicals: €781,089 [14%], and standard treatment: €1,156,520 [22%)]). Mean crude expenditure per patient in Western Europe (Eastern Europe) with Crohn's disease: investigations €1803 (€2160) (P = 0.44), surgery €11,489 (€13,973) (P = 0.14), standard treatment €1027 (€824) (P = 0.51), and biologicals €7376 (€8307) (P = 0.31). Mean crude expenditure per patient in Western Europe (Eastern Europe) with ulcerative colitis: investigations €1189 (€1518) (P < 0.01), surgery €18,414 (€12,395) (P = 0.18), standard treatment €896 (€798) (P < 0.05), and biologicals €5681 (€72) (P = 0.51). Conclusions: In this population-based unselected cohort, costs during the first year of disease were mainly incurred by investigative procedures and surgeries. However, biologicals accounted for >15% of costs. Long-term follow-up of the cohort is needed to assess the cost-effectiveness of biological agents.
KW - Crohn's disease
KW - Economics of IBD therapies
KW - Epidemiology
KW - Outcomes research
KW - Ulcerative colitis
UR - http://www.scopus.com/inward/record.url?scp=84925827444&partnerID=8YFLogxK
U2 - 10.1097/MIB.0000000000000250
DO - 10.1097/MIB.0000000000000250
M3 - Article
AN - SCOPUS:84925827444
SN - 1078-0998
VL - 21
SP - 121
EP - 131
JO - Inflammatory Bowel Diseases
JF - Inflammatory Bowel Diseases
IS - 1
ER -